Semaglutide vs Tirzepatide: How the Two Leading GLP-1 Medications Compare

The short answer

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates a second gut hormone pathway in addition to the one semaglutide targets.

In clinical trials, tirzepatide has produced greater average weight loss than semaglutide. Both are weekly injections, both are made by large pharmaceutical manufacturers, and both carry a similar profile of gastrointestinal side effects.

How each one works in the body

GLP-1 is a hormone your gut releases after you eat. It tells the pancreas to release insulin when blood sugar is high, slows how quickly the stomach empties, and signals fullness to the brain. Semaglutide is a long-acting synthetic version of that hormone, which is why one injection lasts a week.

Tirzepatide does the same thing at the GLP-1 receptor, and also activates the GIP receptor. GIP is a second incretin hormone involved in insulin release and fat metabolism. The working theory is that hitting both pathways produces a larger metabolic effect than hitting one, which is consistent with what the trial data shows.

• •Both slow gastric emptying, which is why nausea and early fullness are the most common complaints on either drug.
• •Both reduce appetite signaling in the brain, often described by patients as quieting 'food noise'.
• •Neither is a stimulant, and neither works by blocking fat absorption.

Weight loss: what the trials actually showed

The pivotal trial for semaglutide 2.4 mg (STEP 1) reported an average body weight reduction of roughly 15% at 68 weeks in adults with obesity or overweight without diabetes.

The pivotal trial for tirzepatide (SURMOUNT-1) reported average reductions of roughly 15% to 21% at 72 weeks depending on the maintenance dose, with the highest dose producing the largest reduction.

SURMOUNT-5, a head-to-head trial comparing tirzepatide with semaglutide in adults with obesity, reported greater average weight reduction on tirzepatide.

Averages are not predictions. Trial populations were supported with lifestyle counseling, and individual results in these trials ranged from minimal loss to well above the average.

Side effects and tolerability

The side effect profiles overlap heavily. The most common issues on both drugs are gastrointestinal, they cluster around dose increases, and they usually ease as the body adjusts.

• •Common: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, fatigue.
• •Less common but serious: pancreatitis, gallbladder problems, kidney injury from dehydration, severe allergic reactions.
• •Both carry a boxed warning about thyroid C-cell tumors observed in rodents. Both are contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• •Slower titration is the standard tool for managing side effects. Many prescribers will hold a patient at a lower dose rather than escalate on schedule.

Cost and access

List prices for brand-name GLP-1s run well over $1,000 per month, though almost nobody pays list. What you actually pay depends on insurance coverage, manufacturer savings programs, direct-to-consumer self-pay pricing from the manufacturers, and whether a telehealth provider bundles medication into a membership.

Coverage is the single biggest cost variable. Many commercial plans cover a GLP-1 for type 2 diabetes but exclude the same molecule when it is prescribed for weight management, which is why the diabetes-labeled and obesity-labeled versions of the same drug can cost wildly different amounts for the same person.

• •Check whether your plan has a separate weight-management benefit before assuming a denial is final.
• •Manufacturer self-pay channels have narrowed the gap between brand-name and compounded pricing since 2025.
• •Telehealth memberships that quote a single monthly number usually bundle the visit, the medication, and support. Read what happens to that number after any introductory period.

Which one should you ask about?

This is a clinical decision, not a shopping decision, and the honest answer is that the better drug is the one you can get, afford, and tolerate.

Tirzepatide has the stronger average weight-loss data. Semaglutide has a longer track record, more approved formulations including an oral tablet, and broader cardiovascular outcome data. If your insurance covers one and not the other, that will usually decide it.

• •Ask your prescriber which molecule your plan covers for your specific indication.
• •Ask what the titration schedule looks like and what happens if you cannot tolerate a dose increase.
• •Ask what the plan is if you stop, since weight regain after discontinuation is well documented for both drugs.

Frequently Asked Questions